Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.7.3273

An Updated Meta-analysis Between the Association of XRCC1 Arg399Gln Polymorphism and Hepatocellular Carcinoma Risk  

Zhang, Xiao-Lian (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University)
Lu, Yu (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University)
Yang, Shi (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University)
Peng, Qi-Liu (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University)
Wang, Jian (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University)
Xie, Li (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University)
Deng, Yan (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University)
He, Yu (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University)
Li, Tai-Jie (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University)
Qin, Xue (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University)
Li, Shan (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.7, 2014 , pp. 3273-3278 More about this Journal
Abstract
Background: Various studies have evaluated the relationship between X-ray repair cross-complementing group 1 (XRCC1) Arg399Gln polymorphism and hepatocellular carcinoma (HCC) risk, but the conclusions have been inconsistent and underpowered. The purpose of this updated meta-analysis was to examine whether XRCC1 Arg399Gln polymorphism confers susceptibility to HCC. Methods: Eligible studies extracted from PubMed, Embase, Cochrane Library, VIP (chinese) and CNKI (chinese) up to November 2013 were included in the study. Pooled odds ratio (OR) together with their 95% confidence interval (CI) were estimated to evaluate XRCC1 Arg399Gln polymorphism and HCC risk. Results: Finally, 21 studies with 4,170 cases and 5,030 controls were involved in our meta-analysis. The results demonstrated that there was significant association between Arg399Gln polymorphism and HCC risk under two contrast models in overall populations (AG vs GG: OR=1.265, 95%CI=1.036-1.545, p=0.021; AA+AG vs GG: OR=1.240, 95%CI=1.021-1.506, p=0.030). In subgroup analyses, significant association was found in Asians (A vs G: OR=1.175, 95%CI=1.013-1.362, p=0.033; AG vs GG: OR=1.317, 95%CI=1.070-1.622, p=0.009; AA+AG vs GG: OR=1.289, 95%CI=1.055-1.575, p=0.013) and Caucasians (A vs G: OR=0.591, 95%CI=0.361-0.966, p=0.036; AA+AG vs GG: OR=0.468, 95%CI=0.234-0.934, p=0.031). Conclusions: The results suggest that XRCC1 Arg399Gln polymorphism may increase HCC risk especially among Asians. However, XRCC1 Arg399Gln polymorphism might act as a protective role against HCC among Caucasians.
Keywords
XRCC1; polymorphism; HCC; meta-analysis; risk;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Li QW, Lu CR, Ye M, et al (2012). Evaluation of DNA repair gene XRCC1 polymorphism in prediction and prognosis of hepatocellular carcinoma risk. Asian Pac J Cancer Prev, 13, 191-4.   과학기술학회마을   DOI   ScienceOn
2 Jung SW, Park NH, Shin JW, et al (2012). Polymorphisms of DNA repair genes in Korean hepatocellular carcinoma patients with chronic hepatitis B: possible implications on survival. J Hepatol, 57, 621-7.   DOI   ScienceOn
3 Kiran M, Saxena R, Chawla YK, et al (2009). Polymorphism of DNA repair gene XRCC1 and hepatitis-related hepatocellular carcinoma risk in Indian population. Mol Cell Biochem, 327, 7-13.   DOI   ScienceOn
4 Caldwell, Park SH (2009). The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol, 44, 96-101.   DOI
5 Chen CC, Yang SY, Liu CJ, et al (2005). Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. Int J Epidemiol, 34, 1310-8.   DOI   ScienceOn
6 Borentain P, Gerolami V, Ananian P, et al (2007). DNA-repair and carcinogen-metabolising enzymes genetic polymorphisms as an independent risk factor for hepatocellular carcinoma in Caucasian liver-transplanted. Eur J Cancer, 43, 2479-86.   DOI   ScienceOn
7 Bose S, Tripathi DM, Sukriti, et al (2013). Genetic polymorphisms of CYP2E1 and DNA repair genes HOGG1 and XRCC1: association with hepatitis B related advanced liver disease and cancer. Gene, 519, 231-7.   DOI   ScienceOn
8 Zeng XY, Yu HP, Qiu XQ, et al (2010). A case-control study of polymorphism of XRCC1 gene and the risk of hepatocellular carcinoma. Chinese J Disease Control Prevent, 760-3.
9 Zhang H, Wang P, Dai L, et al (2010). Meta-analysis of the relationship between polymorphisms of 399 point of X-ray repair cross complementing gene group 1 and hepatocellular carcinoma. Wei Sheng Yan Jiu, 39, 664-8.
10 Jia F, Su H, Li X (2010). Polymorhisms of UGT1A7 and XRCC1 are Associated with an Increased Risk of Hepatocellular Carcinoma in Northeast China. Chinese J Cancer Res, 260-6.
11 Hoeijmakers JH (2001). Genome maintenance mechanisms for preventing cancer. Nature, 411, 366-74.   DOI   ScienceOn
12 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
13 Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.   DOI   ScienceOn
14 Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.   DOI   ScienceOn
15 He GZ, Hung TR, Deng W, et al (2012). Research on Association Between XRCC1 Arg399Gln Polymorphism and Liver Cancer. Journal of Guangxi University Of Chnese Medicine, 1-3.
16 Han X, Xing Q, Li Y, et al (2012). Study on the DNA repair gene XRCC1 and XRC3 polymorphism in prediction and prognosis of hepatocellular carcinoma risk. Hepatogastroenterology, 59, 2285-9.
17 Han YN, Yang JL, Zheng SG, et al (2004). Study on the association of human XRCC1-399 single nucleotide polymorphism and primary hepatocytic carcinoma. Chinese Hepatology, 235-7.
18 Gulnaz A, Sayyed AH, Amin F, et al (2013). Association of XRCC1, XRCC3, and XPD genetic polymorphism with an increased risk of hepatocellular carcinoma because of the hepatitis B and C virus. Eur J Gastroenterol Hepatol, 25, 166-79.   DOI
19 Hagymasi K, Tulassay Z (2008). [Epidemiology, risk facors and molecular pathogenesis of primary liver cancer]. Orv Hetil, 149, 541-8 (in Hungarian).   DOI   ScienceOn
20 Guo LY, Jin XP, Niu W, et al (2012). Association of XPD and XRCC1 genetic polymorphisms with hepatocellular carcinoma risk. Asian Pac J Cancer Prev, 13, 4423-6.   과학기술학회마을   DOI   ScienceOn
21 Farazi PA, DePinho RA (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 6, 674-87.   DOI   ScienceOn
22 Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.   DOI   ScienceOn
23 Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55.   DOI   ScienceOn
24 Gomaa AI, Khan SA, Toledano MB, et al (2008). Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol, 14, 4300-8.   DOI   ScienceOn
25 Egger M, Davey Smih G, Schneider M, et al (1997). Bias in meta-analysis betected by a simple, graphical test. BMJ, 315, 629-34.   DOI   ScienceOn
26 El-Serag HB (2011). Hepatocellular carcinoma. N Engl J Med, 365, 1118-27.   DOI   ScienceOn
27 DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.   DOI   ScienceOn
28 Ding F, Chen YY, Xie Y, et al (2012). Correlation between XRCC1 genetic Polymorphism Arg399Gln and susceptibility to hepatocellular carcinoma in liver caner family clusters in Fusui county, Guangxi. Chinese J Oncol preve Treat, 33-7.
29 Yang JL, Han YN, Zheng SG, et al (2004). Influence of human XRCC1-399 single nucleotide polymorphism on primary hepatocytic carcinoma. Tumor, 322-4.
30 Almeida KH, Sobol RW (2007). A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair, 6, 695-711.   DOI
31 Yu MW, Yang SY, Pan IJ, et al (2003). Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst, 95, 1485-8.   DOI   ScienceOn
32 Wu D, Jiang H, Gu Q, et al (2013). Association between XRCC1 Arg399Gln polymorphism and hepatitis virus-related hepatocellular carcinoma risk in Asian population. Tumour Biol, 34, 3265-9.   DOI   ScienceOn
33 Wu H (2009). Correlation between DNA repair gene XRCC1 single nucleotide polymorphism and susceptibility to hepatocellular carcinoma in Fusui county of Guangxi. Guangxi Medical Unibersity.
34 Vidal AE, Boiteux S, Hickson ID, et al (2011). XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. EMBO J, 20, 6530-9.
35 Shen MR, Jones IM, Mohrenweiser H (1998). Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res, 58, 604-8.
36 Su HY (2008). A case-control study on association between genetic polymorphisms of DNA repair and hepatic cell cancer susceptibility. China Medical University.
37 Tang YT, Li XP, Liu TQ, et al (2011). Genetic polymorphisms of DNA repair genes in patients with hepatocellular carcinoma. Shandong Med J, 19-20.
38 Ren Y, Wang DS, Li Z, et al (2008). Study on the relationship between gene XRCC1 codon 399 single mucleotide polymorphisms and primary hepatic carcinoma in Han nationality. J Clin Hepatol, 361-4.
39 Sato K, Mori M (2011). Evolving molecular mechanism-based strategies for control of hepatocellular carcinoma. Curr Med Chem, 18, 4375-88.   DOI
40 Masson M, Niedergang C, Schreiber V, et al (1998). XRCC1 is specifically associated with poly (ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol, 18, 3563-71.   DOI
41 Mei J, Duan HX, Wang LL, et al (2013). XRCC1 polymorphisms and cervical cancer risk: an updated meta-analysis. Tumour Biol, 35, 1221-31.
42 Mohana Devi S, Balachandar V, Arun M, et al (2013). Analysis of genetic damage and gene polymorphism in hepatocellular carcinoma (HCC) patients in a South Indian population. Dig Dis Sci, 58, 759-67.   DOI   ScienceOn
43 Long XD, Ma Y, Wei YP, et al (2005). X-ray repair cross-complementing group 1 (xrcc1) arg 399 gln polymorphism and aflatoxin b1 (afb1)-related hepatocellular carcinoma (hcc) in guangxi population. Chinese J Cancer Res, 17-21.
44 Pan HZ, Liang J, Yu Z, et al (2011), Polymorphism of DNA repair gene XRCC1 and hepatocellular carcinoma risk in Chinese population. Asian Pac J Cancer Prev, 12, 2947-50.
45 Poehlmann A, Roessner A (2010). Importance of DNA damage checkpoints in the pathogenesis of human cancers. Pathol Res Pract,206, 591-601.   DOI   ScienceOn
46 Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
47 Long XD, Ma Y, Wei YP, et al (2006). The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China. Hepatol Res, 36, 48-55.   DOI   ScienceOn
48 Long XD, Ma Y, Wei YP, et al (2004). Polymorphism of DNA repair gene XRCC1 and risk of hepatocellular carcinoma. J Guangxi Medical University, 313-5.
49 Li S, Peng Q, Chen Y, et al (2013). DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk: A meta-analysis. PLoS One, 8, 73448.   DOI
50 Kirk GD, Turner PC, Gong Y, et al (2005). Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer Epidemion Biomarders Prev, 14, 373-9.   DOI   ScienceOn
51 Li J, Li Z, Feng L, et al (2013). Polymorpisms of DNA repair gene XRCC1 and hepatocellular carcinoma risk among East Asians: a meta-analysis. Tumour Biol, 34, 261-9.   DOI   ScienceOn